Injeq’s IQ-Tip® needle receives CE certification – the Finnish innovation is ready for sales to the European market

The medical technology company Injeq’s development yielded the desired outcome after many years of efforts as the company’s IQ-Tip® needle received CE approval on December 21, 2021. The needle can be used in lumbar punctures from newborns to the elderly, treatment punctures of children with leukemia being one of the main indications. For medical devices, the CE certification translates to a marketing authorization in Europe. In other words, the company can expect a new era of growth as a result of the certification.

Injeq IQ-Tip® is revolutionary as it knows exactly where the needle tip is. The aim of this feature is to make challenging punctures easier for physicians and to promote patient safety. The first commercial application of the needle is intended for lumbar punctures, where the IQ-Tip® system gives an audiovisual alarm when the needle tip detects cerebrospinal fluid during the procedure.

“For medical devices, the CE certification translates to a marketing authorization. We have now been able to launch the commercialization measures we have been preparing for the Europe and the first deliveries to Germany have already been made. CE approval is a result of the team’s long-term development work and hard final efforts”, says Tommi Rasila, Injeq’s Chairman of the Board of Directors and Interim CEO.

CE certification has been granted for the IQ-Tip® needle under the stringent Medical Device Regulation (MDR) of the EU. The regulatory requirements of medical devices changed during the development project, pushing Injeq into considerable additional work and efforts, including new clinical investigations. The work was completed in the autumn of 2020. The conformity of the Injeq IQ-Tip® system was assessed by the distinguished Notified Body, TÜV SÜD Product Service GmbH in Germany.

The CE certification demonstrates that the medical device fulfils all requirements set and is in compliance with all relevant regulations. Medical devices are divided into three risk classes according to their intended purpose and related risks. Injeq IQ-Tip® needle is a class III medical device, which is subject to the strictest requirements, and is one of the first MDR 2017/745 certified new products in this category in Finland. The analyzer of the IQ-Tip® system is a class IIa device, and the special cable is a sterile class I device, which were certified by the Notified Body already in June 2021.

“The device must fulfil the requirements of the MDR throughout its life cycle in terms of product safety, clinical performance, risk management and follow-up. As a medical device manufacturer we must have a certified quality management system, which is subject to annual audits”, says Jussi Seitsonen, Head of Quality.

Injeq’s first goal will be to bring the IQ-Tip® system as a part of routine treatment practices of children with leukemia and neonates in Europe. During the first year, Injeq aims to find clinical reference users, particularly in leading university hospitals. The future goal is to facilitate challenging lumbar punctures of adults, and later, other demanding punctures, starting from Europe and expanding around the world.

For additional information, please contact:

Injeq Oy

Chairman of the Board of Directors and Interim CEO Tommi Rasila

tel. +358 40 750 8158

tommi.rasila@injeq.com

Injeq in brief

Injeq Oy is a Finnish growth company specializing in medical technology and aiming to produce intelligent technical solutions for demanding medical punctures and injections.

The company’s lead product, the IQ-Tip® needle system, is a state-of-the-art solution for the safe execution of demanding patient punctures, with the initial main focus on lumbar punctures. Lumbar puncture is a procedure where cerebrospinal fluid samples are taken or medication is injected into the spinal canal. The clinical performance and safety of the product have been evaluated in three clinical investigations at university hospitals. Inspired by physicians’ wishes and needs, the IQ-Tip® needle system facilitates performing punctures with the final aim to improve patient safety and effectiveness of treatment. The needle can be used in lumbar punctures from newborns to the elderly, treatment punctures of children with leukemia being one of the main indications.

Established in 2010, Injeq is based in Tampere and currently employs 16 people. Injeq operations are founded on experienced team of medical experts and extensive scientific research.

German reseller Florian Holderer was dazzled by the smart needle

Ecumed’s CEO Florian Holderer emphasizes the importance of user experience and trust in the marketing of the IQ-Tip®​ smart needle. Florian Holderer […]
Read more »

Changes to the Injeq Plc. Board

The Annual General Meeting held on May 31 2022 made the regular decisions as defined in the by-laws. The new […]
Read more »

Incidence of traumatic lumbar punctures in neonates and infants

The part two of the trilogy has now been published. This article of the three part series examines the incidence […]
Read more »

Injeq whitepaper on lumbar puncture

Our whitepaper takes a closer look at the lumbar puncture, the IQ-Tip® system’s first indication, and presents the results that […]
Read more »

Bioimpedance spinal needle provides high success and low complication rate in lumbar punctures of pediatric patients with acute lymphoblastic leukemia

The great results of our latest clinical investigation have now been published as an open access article in Scientific Reports, […]
Read more »

Injeq Oy Shares Have Been Transferred to Finnish Book-Entry Securities System – Instructions for Shareholders

Injeq Oy Annual General Meeting resolved on 26th May 2021 to transfer the shares of the company into the Finnish […]
Read more »